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Abstract 
Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, 
high interstitial pressure, and resistant tumor microenvironment.  We have developed a combination 
therapy that can significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis 
in the tumor center while simultaneously increasing nanoparticle uptake through a treatment-induced 
increase in the accumulation and retention of nanoparticles in the tumor.  The vascular disrupting agent 
Combretastatin A-4 Phosphate (CA4P) is able to increase the accumulation of radiation-containing 
nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is 
maintained over several days.  We use ultrasound to measure the effect of CA4P in live tumor-bearing 
mice, and we encapsulate the radio-theranostic isotope 177Lutetium as a therapeutic agent as well as a 
means to measure nanoparticle accumulation and retention in the tumor.  This combination therapy 
induces prolonged apoptosis in the tumor, decreasing both the fibroblast and total cell density and 
allowing further tumor growth inhibition using a cisplatin-containing nanoparticle. 
Key words: Cancer, Theranostic, Nanoparticle, CA4P, EPR, Desmoplastic, Cisplatin. 
Introduction 
We have previously published on the antitumor 
efficacy of our 177Lutetium (177Lu)-loaded 
Lipid-Calcium-Phosphate (177Lu-LCP) nanoparticles, 
which provide internal radiation therapy via the beta 
decay of 177Lu as well as live animal imaging via 
177Lu’s gamma decay [1].  One dose of these 
nanoparticles generated significant and prolonged 
tumor growth inhibition in two subcutaneous 
xenograft tumor models with initial tumor volumes of 
100-150 mm3.  The success of this approach prompted 
us to gauge whether the antitumor effect could be 
maintained in larger tumors, which present a number 
of additional, clinically relevant challenges to delivery 
and treatment success, including an increased growth 
rate, a more mature and resistant stromal 
structure/microenvironment, and increased 
interstitial pressure that can decrease nanoparticle 
accumulation.  Successful strategies against these 
large, aggressive, and often desmoplastic 
(stroma-rich) tumors may therefore translate more 
effectively into positive patient outcomes in the clinic.  
The UMUC3 human bladder cancer model, 
supplemented with murine NIH/3T3 fibroblasts, is 
histologically similar to desmoplastic bladder cancer 
seen in the clinic and responds to treatment similarly 
to patient bladder cancer as well [2].  Although 
smaller UMUC3/3T3 tumors were shown to be 
sensitive to 177Lu-LCP, we show in Figure 4 of this 
paper that in our large UMUC3/3T3 tumor model 
(initial tumor volumes ~300-400 mm^3; Volume = 
(Length x Width x Depth)/2), 177Lu-LCP monotherapy 
no longer induces a significant antitumor effect.  We 
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therefore designed a combination therapy in which 
the small molecule drug and radiosensitizer [3, 4] 
Combretastatin A-4 Phosphate (CA4P) is used 
alongside our radioactive nanoparticles to induce a 
multifaceted synergistic effect. 
The microtubule inhibitor CA4P works by 
binding to the alpha-beta tubulin heterodimer in the 
cell cytoplasm and preventing microtubule 
polymerization.  Because cellular spindle fibers are 
composed of microtubules, this action has a cytotoxic 
effect on actively dividing cells in vitro, preventing 
separation of chromosomes during mitosis and 
leading to cell death via mitotic catastrophe [5].   
Treatment with the vascular disrupting agent 
CA4P also generates a tumor-selective mechanism of 
cytotoxicity in vivo [3, 6, 7].  During tumor growth, 
angiogenesis of new blood vessel endothelium occurs, 
and these endothelial cells must maintain a flat 
structure in order to provide a stable and open blood 
vessel lumen.  While the cytoskeletons of mature 
vasculature, such as those found in healthy tissue, are 
composed of actin, the cytoskeletons of newly formed 
tumor vasculature are composed of microtubules [3, 
8].  It has been hypothesized that when microtubule 
polymerization is inhibited by CA4P, the flat structure 
of only the tumor endothelial cells is compromised, 
causing them to become more round and occlude the 
lumen of the blood vessel [9].  This decreases blood 
flow to the center of the tumor, depriving the cells of 
oxygen and nutrients.  In extreme cases, the 
destruction of blood vessel integrity has been shown 
to cause hemorrhage and subsequent necrosis of the 
surrounding region.  Because mature, healthy 
vasculature has a cytoskeleton made of actin and 
healthy cells do not frequently divide, CA4P has very 
low toxicity to healthy tissue and is tolerable in mice 
at doses well above 100 mg/kg [6].   
It is important to note that vascular disrupting 
agents such as CA4P are distinct from anti-angiogenic 
agents.  Anti-angiogenic agents are used to prevent 
the formation of new blood vessels and are most 
effective when treating small tumors or metastases in 
order to prevent significant blood vessel formation 
and growth [6].  In contrast, vascular disrupting 
agents work to destroy existing blood vessels in the 
tumor, and are particularly suited for treating large, 
resistant tumors by causing secondary necrosis in the 
middle of the tumor [10].  
A recent publication that has used CA4P in 
combination with nanoparticles has reported that the 
CA4P-induced vessel occlusion limited nanoparticle 
accumulation to the outer rim of the tumor [11], but 
we have alternatively found that the intratumoral 
hemorrhage induced by CA4P allows an increased 
accumulation of nanoparticles throughout the tumor.  
This additional dose was retained in the tumor over 
several days, and the sustained higher dose combined 
with the destructive effects of CA4P significantly 
inhibited tumor growth even in our large, stroma-rich 
tumor model.  
Materials and Methods 
Materials 
177LuCl3 and 90Yttrium (90Y)Cl3 were purchased 
from PerkinElmer (Waltham, MA).  1,2-dioleoyl-sn- 
glycero-3-phosphate (DOPA), and 1,2-dioleoyl-3- 
trimethylammonium-propane (DOTAP) were 
purchased from Avanti Polar Lipids (Alabaster, AL).  
N-(Carbonyl-methoxypolyethyleneglycol 2000)-1,2- 
distearoyl-sn-glycero-3-phosphoethanolamine, 
sodium salt (DSPE-PEG2000) was purchased from 
NOF America Corporation (White Plains, NY).  
DSPE-PEG2000-Anisamide (DSPE-PEG-AA) was 
synthesized in our lab as described previously [12].  
Other chemicals and antibodies were purchased from 
Sigma-Aldrich (St. Louis, MO) or Abcam (Cambridge, 
MA). 
Cell Lines 
Four different cell lines were used in the 
experiments described below: UMUC3 human 
bladder cancer cells, NIH/3T3 (3T3) murine 
fibroblasts, 4T1 murine breast cancer cells, and B16F10 
murine melanoma cells.  In some experiments, 
UMUC3 cells that had been stably transfected with 
green fluorescence protein (GFP) and 3T3 cells that 
had been stably transfected with red fluorescence 
protein (RFP) were used. 
Experimental Animals 
Female athymic nude mice were used for 
UMUC3/3T3 tumor experiments presented in this 
manuscript.  Balb/c mice were used as syngeneic 
hosts for 4T1 tumor inoculation, C57Bl/6 mice were 
used as syngeneic mice for B16F10 tumor inoculation, 
and CD-1 mice were used for toxicity studies.  The 
nude mice were purchased from the National Cancer 
Institute (Bethesda, MD) and bred at the Division of 
Laboratory Animal Medicine at the University of 
North Carolina-Chapel Hill.  The Balb/c, C57Bl/6, 
and CD-1 mice were purchased from Charles River 
labs.  All work performed on these animals was 
approved by the Institutional Animal Care and Use 
Committee at the University of North 
Carolina-Chapel Hill, protocol #14-045. 
177Lu-LCP, 90Y-LCP, and LPC Fabrication and 
Characterization 
The Lipid-Platinum-Chloride (LPC) 
nanoparticles were fabricated exactly as described in 
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the literature [13].  LPC encapsulation of CDDP was 
determined by nuclear magnetic resonance and X-ray 
photoelectron spectroscopy, and drug loading of 
cisplatin (cis-diamminedichloridoplatinum(II), or 
CDDP) was determined by Inductively Coupled 
Plasma Mass Spectroscopy (ICP-MS).  177Lu/90Y-LCP 
fabrication was slightly modified from what is 
described in a previous publication [1].  Two reverse 
microemulsions were prepared in round-bottom 
flasks.  Both microemulsion oil phases contained a 
mixture of 71% Cyclohexane and 29% Igepal CO-520.  
For a batch size of 1.67 mL oil phase per flask, 50 μL of 
200 mM (NH4)2PO4 was added to one flask and 50 μL 
of 2.5 M CaCl2 with up to five additional μL of 
177LuCl3 or 90YCl3 in 0.05 M HCl was added to the 
other under stirring.  After mixing separately for five 
min, the phosphate-containing emulsion was added 
directly to the calcium-containing emulsion.  After 
five more min, 26.6 μL of 25 mg/mL DOPA dissolved 
in chloroform was added to the mixture.  After 20 
more min of mixing, 3.34 mL of 100% ethanol was 
added to break the emulsion, and the mixture was 
stirred for 10 more minutes before centrifugation at 
12,600g for 15 min.  The supernatant was then 
removed (~15% of input 177Lu was removed here) and 
ethanol was again added to wash the pelleted cores.  
After addition of ethanol, the vial(s) were vortexed to 
resuspend the nanoparticle cores and centrifuged at 
12,600g for 10 min.  After removing the supernatant, 
the organic-soluble cores were dissolved in 
chloroform and centrifuged again to remove any 
insoluble salts or particles that had not been 
well-coated with DOPA (~5% of input removed here). 
Purifying the LCP cores in these two ways ensured 
that 177Lu or 90Y were only present inside the LCP.  
Outer leaflet lipids (OLLs) dissolved in chloroform 
were then added to the chloroform-soluble cores 
(40:40:18:2 DOTAP:cholesterol:DSPE-PEG2000:DSPE- 
PEG2000-AA mol:mol:mol) (0.11:1 total OLL:initial oil 
phase v:v; all lipids at 20mM concentration).  In 
experiments using fluorescent 1,1’-Dioctadecyl- 
3,3,3’,3’-Tetramethylindocarbocyanine Perchlorate 
(DiI)-labeled LCP, DiI dissolved in chloroform was 
added to the cores with the OLLs (1:100 DiI:total OLL 
mol:mol).  Chloroform was evaporated until the 
particles and lipids coated the vial in a lipid film.  
Particles were then rehydrated to the injection volume 
with 5% glucose in water at 60 oC.  The solution was 
vortexed and sonicated liberally before injection into 
mice.  The anisamide ligand was used in all 
formulations to target the sigma receptor 
overexpressed in UMUC3 cells [14]. 
In experiments using DiI-labeled Lu-LCP, 
sucrose gradient ultracentrifugation (50,000g for 6 h) 
was used to purify DiI-Lu-LCP from excess DiI that 
had incorporated into excess free liposomes.   
Encapsulation efficiency of 177Lu into 177Lu-LCP 
was measured by a Model AA2010 “Nucleus” 
Gamma Scintillation Counter or a Capintec 
Radioisotope Calibrator CRC-127R and calculated as 
(signal from 177Lu in LCP cores)/(signal from 177Lu in 
input aqueous phase).  Although 90Y is a pure beta 
emitter, secondary emissions were able to be used to 
calculate the encapsulation efficiency of large doses of 
90Y-LCP using the CRC-127R.  Encapsulation 
efficiencies for 177Lu and 90Y into LCP were both found 
to be ~80-85% of the input.  The encapsulation 
efficiency of CDDP into LPC was only ~20% of the 
input, but the % drug loading of CDDP into LPC 
nanoparticles was ~80%, consistent with the 
literature[13].  177Lu-LCP, 90Y-LCP, and LPC 
hydrodynamic diameters, polydispersity indices 
(PDI), and zeta potentials were measured using a 
Malvern Nano ZS dynamic light scattering 
instrument.  Particle size was corroborated using 
transmission electron microscopy (TEM).   
The stability of LCP after sonication and 
vortexing was quantified using ultracentrifugation 
across a water-sucrose boundary, as nanoparticles in 
water should move down across the sucrose gradient 
during centrifugation due to their high density, while 
free 177Lu atoms should remain at the top layer, only 
slowly diffusing across the sucrose barrier.  Three 
different groups were tested, each in duplicate.  In the 
177Lu-LCP group receiving vortexing and sonication, 
water was added to the lipid film to hydrate the 
particles, followed by ten seconds of vortexing and 
ten seconds of sonication.  In the 177Lu-LCP group 
receiving no vortexing or sonication, water was added 
to hydrate the particles and the water was gently 
swirled in the vial.  In the free 177Lu group, 177LuCl3 
was diluted in water.  Each sample of 250 μl was 
carefully added on top of a layer of 10% w/v sucrose 
in water in an ultracentrifuge tube.  The samples were 
spun at 50,000 RPM for 5 h, and then the top 400 μl of 
liquid was collected from each tube.  The percentage 
of total 177Lu signal in the top 400 μl was compared 
across all groups.   
To quantify the release of 177Lu from 177Lu-LCP 
in pH 7.4 tris-buffered saline at 37oC, 177Lu-LCP was 
dialyzed using 3K molecular weight cutoff 
Slide-A-Lyzer mini dialysis devices (Thermo Fisher, 
Waltham, MA) and the un-dialyzed supernatant was 
periodically measured for 177Lu activity using gamma 
scintillation. 
Cell Viability Assay 
UMUC3 and 3T3 cells were seeded at a density 
of 2,500 cells/well in a 96-well culture plate.  UMUC3 
cells were incubated in 200 µL/well of Dulbecco’s 
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Modified Eagle Medium (DMEM) containing 10% 
fetal bovine serum and 1% penicillin/streptomycin, 
and 3T3 cells were incubated in 200 µL/well DMEM 
containing 10% bovine calf serum and 1% 
penicillin/streptomycin. 24 h later, escalating doses of 
CA4P were added to the cell culture media, n = 6 for 
each cell type.  After 48 h, 20 μL of working 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoli
um bromide (MTT) solution was added to each well.  
~2 h later, the media was carefully aspirated and 
replaced with 200 μL Dimethyl Sulfoxide (DMSO) in 
order to solubilize the MTT product.  The DMSO was 
mixed thoroughly to ensure complete dissolution of 
the product, and each well was measured for 
absorbance at 570 nm.  Cell viability was calculated as 
percent of untreated wells. 
CA4P Vessel Occlusion   
Nude mice bearing subcutaneous UMUC3/3T3 
tumors were sedated with isofluorane and an 
intravenous catheter was inserted into the tail vein.  
Mice were transferred to a heated stage and 
ultrasound gel was used to couple a 15L8 ultrasound 
transducer to the tissue.  An Acuson Sequoia 512 
ultrasound system (Siemens Corporation, 
Washington DC, USA) was used to capture contrast 
images and parametric maps of blood perfusion. 
Preclinical ultrasound microbubble contrast agents 
composed of a phospholipid shell and a 
perfluorocarbon core (diameter ~ 2 μm) were 
manufactured in house and injected into circulation 
for the contrast imaging experiments.  Microbubbles 
were continuously infused until a steady state 
concentration in the blood was reached.  A 
quantitative measure of perfusion was obtained using 
a technique called “Destruction Reperfusion”, where 
bubbles are cleared from the imaging plane using 
high-amplitude ultrasound pulses, and the tissue is 
monitored as microbubbles replenish the tissue [15, 
16].  Parametric perfusion maps were generated using 
proprietary Sequoia software; the time necessary for 
each pixel to regain 20% of its original intensity before 
destruction was measured and displayed in a 
colormap ranging between fast (green) and slow (red) 
perfusion as can be seen in the figure. The reperfusion 
was monitored for 20 seconds after destruction, and a 
3D perfusion map was captured by sweeping the 
transducer across the tumor and performing 
destruction reperfusion at several locations, using a 
1mm step size.  The thickness of each section was 0.4 
mm, equal to the width of the ultrasound beam. The 
area that was not reperfused in that time frame, 
shown in black, was quantified and averaged for all 
sections in four separate tumors.  After this initial 
baseline value was recorded, the mouse was treated 
intraperitoneally (i.p.) with 100 mg/kg CA4P.  At t = 3 
h and 24 h after treatment, the same four mice were 
again imaged in the same manner as before. 
Effects of CA4P on UMUC3/3T3 Tumors 
Mice bearing UMUC3/3T3 tumors ~300-400 
mm3 in volume were either treated i.p. with 100 
mg/kg CA4P in 200 μL of phosphate-buffered saline 
(PBS) or left untreated.  24 h after treatment, the mice 
were sacrificed and their tumors were dissected.  
Tumors were fixed in 10% formalin for 48 h, 
embedded in paraffin, and sectioned.  Three adjacent 
sections were stained for apoptosis (using terminal 
deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL), Promega), blood vessels (CD-31 
immunofluorescence, Abcam), and Masson’s 
Trichrome.  The Aperio Scanscope at UNC’s 
Translational Pathology lab was used to acquire 
images of the entire tumor section.  Sections were 
overlaid using ImageJ.   
Tumor Growth Inhibition Studies 
Four different tumor growth inhibition 
experiments were performed in this study.  In all 
cases, initial tumor volumes for each group averaged 
~300-400 mm3, calculated as Volume = (Length x 
Width x Depth)/2.  Digital calipers were used to 
measure the greatest diameter of the tumor (length), 
the greatest diameter in the perpendicular dimension 
(width), and the greatest thickness of the tumor in the 
direction perpendicular to both length and width 
(depth).  To measure depth, mice were first restrained 
by the tail while standing on their cage.  The tumor 
was rocked to the side using the hand holding the tail, 
and the other hand was used to measure the tumor’s 
depth using the digital calipers.  This method was 
facile and reproducible.  Five million UMUC3 cells 
and 2.5 million 3T3 cells were inoculated in a total 
volume of 100 μL and in a 1:3 matrigel:PBS solution 
(Corning Matrigel Matrix, High Concentration).  
Tumor volumes were measured daily.  In groups 
receiving CA4P, CA4P was always dissolved in PBS 
and administered i.p. in a total of 200 ul.  Groups 
receiving 177Lu-LCP always received a dose of 250 
microCuries (μCi) administered i.v. via the tail vein.  
Groups receiving 90Y-LCP always received a dose of 
125 μCi administered i.v. via the tail vein.  Groups 
receiving a combination therapy always received 
CA4P 3 h before LCP. 
Tumor Accumulation and Retention of 177Lu 
UMUC3/3T3, 4T1, and B16F10 tumors were 
inoculated in nude, Balb/c, and C57Bl/6 mice, 
respectively.  When tumors reached ~300-500 mm3, 
half were treated with CA4P followed by a known 
amount of 177Lu-LCP at t = 3 h, and half were treated 
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with 177Lu-LCP only.  Twenty-four h later, the mice 
were sacrificed and their tumors were dissected.  
Tumor accumulation of 177Lu was quantified via 
gamma scintillation.  After quantification, the tumors 
were incubated in formamide for 48 h at 60 oC to show 
the blood in the tumor centers that had been treated 
with CA4P.  Separate UMUC3/3T3 tumors were 
treated with purified DiI-Lu-LCP and dissected 24 h 
after treatment.  These tumors were fixed for 48 h in 
10% formalin at 4 oC, incubated in 30% sucrose in PBS 
overnight, and then frozen in optimal cutting 
temperature (OCT) reagent.  After cutting into the 
middle of each tumor, a photograph was taken to 
show the extent of the blood-filled region, and two 
adjacent sections were cut.  One section was imaged 
to show the distribution of DiI in the tumor, and the 
second section was stained with Masson’s trichrome 
to show the morphology of the section. 
Measurement of 177Lu-LCP retained in the tumor 
over several days was also quantified by gamma 
scintillation of dissected tumors once those tumors 
reached a volume of 1000 mm3. 
Prolonged Tumor Necrosis 
Mice bearing UMUC3/3T3 tumors ~300-400 
mm3 in volume were treated with 100 mg/kg CA4P 
only or with 177Lu-LCP or 90Y-LCP 3 h after CA4P 
treatment.  Four days after treatment, mice were 
sacrificed and tumors were dissected.  Tumors were 
cut into 3-5 pieces to facilitate fixation and were fixed 
in 10% formalin for 48 h at 4 oC before being 
embedded in paraffin.  Tumor sections were cut and 
two sections 8 µm apart were stained in two different 
ways: the first was stained for apoptosis with the 
TUNEL assay and the second was 
3,3’-Diaminobenzidine (DAB)-stained using 
immunohistochemistry (IHC) against the Ki-67 
proliferation marker.  The images taken from these 
two nearby sections were overlaid using ImageJ in 
order to compare distribution of apoptosis and 
proliferation. 
Treatment-Induced Changes in 
Microenvironment 
Mice were inoculated with UMUC3 cells stably 
expressing green fluorescence protein and 3T3 cells 
stably expressing red fluorescence protein in the same 
manner as described above.  Treatment began when 
tumors reached a volume of ~300-400 mm3.  On day 
seven after treatment, the tumors were dissected, cut, 
and fixed in 10% formalin for 48 h, followed by 
incubation in 1:1 PBS:OCT overnight and freezing in 
100% OCT.  Representative tumors were sectioned 
and two adjacent sections were used for 
quantification.  One section was stained with 
4’6-Diamidino-2-Phenylindole (DAPI) only using 
Prolong Gold Antifade mounting medium (Thermo 
Fisher, Waltham, MA) and was used to compare the 
distribution of green UMUC3 cells and orange 3T3 
cells.  The other section was DAB-stained using IHC 
against cleaved Caspase 3 to measure apoptosis.  In 
order to gain appropriate resolution for 
quantification, multiple random fields (~4 mm2) from 
multiple tumors were used to quantify fibroblast 
density, total cell density, and apoptotic cells. 
Additional Treatment with 
Cisplatin-Containing LPC 
Mice were inoculated with UMUC3/3T3 tumors 
as described above.  At the time of study initiation, 
there were two groups comprised of tumors ~300-400 
mm3 in volume.  One group remained untreated, 
while the other group received 100 mg/kg CA4P + 
125 μCi 90Y-LCP.  When the untreated group reached 
an average volume of ~ 800 mm3, half of the tumors 
received 1.5 mg/kg cisplatin formulated in the LPC 
nanoparticle, and the other half of the tumors received 
no additional treatment.  When the group receiving 
CA4P + 90Y-LCP reached an average volume of ~ 800 
mm3, half of those tumors received 1.5 mg/kg 
cisplatin formulated in the LPC nanoparticle, and the 
other half of the tumors received no additional 
treatment.  Tumor volumes were measured daily and 
mice were sacrificed t = 10 days after the initial 
treatment. 
To test nanoparticle accumulation in previously 
treated and untreated tumors, 300-400 mm3 tumors 
were treated with CA4P + 90Y-LCP or left untreated, 
and six days later all tumors were injected with 
177Lu-LCP.  24 h later, the mice were sacrificed and the 
tumor accumulation of 177Lu was measured via 
gamma scintillation counting. 
Toxicity Studies 
CD-1 mice were treated with several 
combination therapies or appropriate controls and 
were sacrificed 10 days after treatment.  Blood and 
organs were dissected.  Serum levels of AST, ALT, 
BUN, and creatinine were measured, and organs were 
stained with H&E to measure any changes in tissue 
morphology.  Whole blood was measured for changes 
in white blood cell count (WBC), hematocrit (HCT), 
mean cell volume (MCV), red blood cell count (RBC), 
hemoglobin count (HGB), and platelet count (PLT).    
Results 
CA4P Monotherapy 
We first desired to gauge the relative toxicity of 
CA4P on UMUC3 and 3T3 cells in vitro, and an MTT 
cell proliferation assay was conducted after the cells 
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were incubated with escalating doses of CA4P for 48 
h.  Both cell lines responded at low doses, both with a 
half maximal inhibitory concentration (IC50) around 
10nM (p < 0.0001 compared to untreated cells for 
UMUC3 and 3T3 cells), indicating the potency of 
microtubule polymerization inhibition on both cell 
types. 
The effects of 100 mg/kg CA4P on the blood 
vessels of large (300-400 mm3), stroma-rich 
UMUC3/3T3 subcutaneous xenograft tumors in vivo 
were also determined.  We used ultrasound 
microbubble contrast agents to measure the perfusion 
of blood through tumors before and after i.p. 
administration of CA4P.  Microbubbles with diameter 
~2 μm were continuously intravenously administered 
via syringe pump during imaging, and an ultrasound 
transducer recorded the distribution of the bubbles in 
several 0.4 mm-thick sections across the entire length 
of the tumor.  The way the transducer moved across 
the tumor is depicted as a cartoon in Figure 2C.  
High-amplitude ultrasound was used to pop the 
bubbles in each section (termed microbubble 
destruction), and time-dependent reperfusion of 
microbubbles back into the section was measured 
over a span of 20 s (Figure 2A).  Areas that were 
quickly reperfused with microbubbles are shown in 
green in Fig 2A, while areas that took a longer time for 
microbubbles to reperfuse are shown in red.  Any area 
that microbubbles did not reperfuse to 20% of the 
steady-state density in the first 20 s after destruction is 
shown as black.  The black areas from each imaged 
section across a tumor were averaged, and the 
quantification is shown in Fig 2B.  Significant blood 
vessel occlusion occurred 3 h after treatment, and 
after 24 h, some but not all of the vessel perfusion had 
normalized.  Preliminary data (not pictured) showed 
that vessel occlusion was greater at t = 3 h after 
treatment than it was at t = 1 h or t = 7 h after 
treatment.  Figure S1 shows videos of real-time 
microbubble reperfusion into the middle section of 
representative treated and untreated tumors at t = 3 h, 
as well as images of the microbubble reperfusion 
pattern in all sections across a single tumor at t = 20s 
after microbubble destruction.  As reported in 
literature, the outer rim of each treated tumor at t = 3 
h did not show significantly decreased perfusion.  It is 
hypothesized that this occurs because these cells can 
be fed by more mature vasculature in the surrounding 
healthy tissue.    
The decrease in blood perfusion caused by CA4P 
generated areas of significant apoptosis 24 h after 
treatment.  Figure 3A (top row of Figure 3) shows a 
low magnification view of untreated tumor sections 
stained in different manners.  From left to right, 
sections are shown with DAPI nuclear stain (blue), 
TUNEL apoptosis stain (green), CD-31 blood vessel 
stain (red), a composite of DAPI, TUNEL, and CD-31, 
and Masson’s trichrome stain.  Figure 3B directly 
below shows a tumor section 24 h after treatment with 
100 mg/kg CA4P.  The middle of this tumor contains 
a large amount of apoptosis as well as a loss of blood 
vessel structure.  Figure 3C shows additional sections 
of tumors treated with CA4P, each with varying 
degrees of apoptosis in response to the CA4P 
treatment.  High-magnification composite images in 
Fig 3D and 3E also show a lower cell density and 
reduced vessel structure in apoptotic regions. 
 
 
Figure 1: UMUC3 and 3T3 proliferation under CA4P dosing in vitro.  Drug incubated with cells for 48 h.  Cell viability expressed as percent of untreated control group.  n = 6.  
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Figure 2: CA4P vessel occlusion.   Nude mice bearing subcutaneous UMUC3/3T3 tumors were imaged using a microbubble ultrasound contrast agent at a baseline level and at 
t = 3 h and 24 h after i.p. administration of 100 mg/kg CA4P.  Untreated group not given CA4P.  Microbubbles estimate speed of blood perfusion in the tumor.  A) Middle section 
of a representative tumor from each group and time point.  B) Quantification of tumor volume that was not perfused to 20% of initial microbubble concentration 20 sec after 
destruction, n = 4.  **p < 0.01; Baseline CA4P compared to CA4P at t = 3 h.  C) Image acquisition scheme. 
 
 
Figure 3: Effects of CA4P on UMUC3/3T3 Tumors.  A) Adjacent untreated tumor sections stained with DAPI (cell nucleus, blue), TUNEL (apoptosis, green), CD-31 
immunostain (blood vessels, red), or Masson’s Trichrome.  Composite image formed from overlay of DAPI, TUNEL, and CD-31 stains.  Scale bar (A, B, C) = 1 mm.  B) Adjacent 
sections of tumor 24 h after mouse was treated with 100 mg/kg CA4P i.p.  Stainings match those in (A).  C) Composite image of four representative treated tumor samples 24 
h after 100 mg/kg CA4P.  D) Zoomed composite image; scale bar = 200 µm.  E) Zoomed composite image; scale bar = 100 µm. 
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Figure 4: In vivo tumor growth inhibition in UMUC3/3T3 stroma-rich bladder cancer subcutaneous xenograft tumor model.  On Day 0, 100 mg/kg CA4P was administered i.p. 
3 h before i.v. treatment with 250 μCi 177Lu, either as 177LuCl3 or formulated as 177Lu-LCP.  No subsequent doses were given.  Initial tumor sizes = 300-400 mm3; n = 5-7; **p<0.01 
compared to 177Lu-LCP. 
 
CA4P + 177Lu-LCP Combination Therapy 
Despite the in vitro and in vivo cytotoxic effects of 
CA4P, treatment with the drug alone is completely 
ineffective against our large, aggressive UMUC3/3T3 
tumor model.  Monotherapy with 177Lu-LCP also does 
not generate any significant tumor growth inhibition, 
although when 177Lu-LCP is given intravenously (i.v.) 
three hours after CA4P is given i.p.—the time at 
which vessel occlusion is highest—tumor growth is 
significantly inhibited compared to 177Lu-LCP alone 
(Figure 4).  In a previous publication, we have shown 
that LCP containing the non-radioactive 175Lu also 
provides no therapeutic effect. 
CA4P increases the “enhanced permeability 
and retention” (EPR) of tumors 
After observing such a marked decrease in 
tumor growth rate, we attempted to determine how 
CA4P and 177Lu-LCP were able to work 
synergistically.  One reason why 177Lu-LCP alone is 
ineffective may be because in large tumors, the high 
interstitial pressure limits accumulation of 
nanoparticles into tumors [17].  We found that while 
the accumulation of 177Lu-LCP was quite low in larger 
UMUC3/3T3 tumors receiving 177Lu-LCP alone, if 
177Lu-LCP was given 3 h after 100 mg/kg CA4P, its 
accumulation significantly increased (Fig 5A).  In two 
additional large tumor models—a 4T1 orthotopic 
breast cancer model syngeneically grown in Balb/c 
mice and a B16F10 subcutaneous melanoma model 
syngeneically grown in C57Bl/6 mice—CA4P 
induced higher tumor accumulation, although for 
tumor models with higher 177Lu-LCP accumulation 
during monotherapy, the increase in tumor 
accumulation after CA4P was less pronounced.  This 
could be related to the natural differences in vessel 
permeability among the models.  While the hard, 
dense UMUC3/3T3 and 4T1 tumors can be described 
as “stroma-vessel” [18] types in which blood vessels 
grow within a stroma/fibroblast structure, the soft 
B16F10 tumors grow much less densely as 
“tumor-vessel” type tumors with leakier vasculature, 
which may contribute to their innately high tumor 
accumulation and insensitivity to changes in 
nanoparticle accumulation after treatment with CA4P. 
Upon cutting a CA4P-treated UMUC3/3T3 
tumor in half at t = 24 h (Fig 5B, right image), a large 
portion of the tumor interior had become filled with 
blood, further suggesting that CA4P had indeed 
compromised the integrity of the blood vessels and 
caused a massive hemorrhage in the tumor.  The 
resulting poorly-perfused pool of blood would 
certainly present as was observed in our ultrasound 
experiments, as the rapid and orderly vascular flow to 
and from the tumor had been destroyed.   
After the 177Lu-LCP accumulation was quantified 
in the tumors used in Fig 5A, the tumors were soaked 
in formamide for 48 h at 60 oC in order to show the 
extent of additional blood stuck in the tumors.  
Representative tumors in Fig 5C show that blood 
pools in both UMUC3/3T3 and 4T1 tumors after 
treatment with CA4P, but does not in untreated 
tumors of a similar size.  The black melanocytes in the 
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B16F10 tumors do not allow us to observe the effect of 
CA4P, but it is known that untreated B16F10 tumors 
are naturally soft and bloody, a fact that was verified 
in this study as well.  Again, this could be why B16F10 
tumors naturally allow greater 177Lu-LCP 
accumulation and are less affected by CA4P. 
The distribution of 177Lu-LCP in the bloody and 
non-bloody regions of CA4P-treated tumors was also 
compared.  We desired to know whether CA4P would 
affect the vessels’ permeability to nanoparticles, and 
whether a significant amount of additional 177Lu-LCP 
would distribute into the blood pool.  The lipid 
bilayer of 177Lu-LCP was therefore labeled with the 
fluorescent small molecule DiI—known to faithfully 
remain in the labeled lipid bilayers [19, 20]—and the 
nanoparticles were purified using sucrose gradient 
centrifugation.  t = 3 h after treatment with CA4P, 
DiI-177Lu-CA4P was given to mice bearing 
UMUC3/3T3 tumors, and 24 h later the mice were 
sacrificed and their tumors were dissected, processed, 
and frozen in OCT.  After cutting into the middle of 
each tumor, a photograph was taken to show the 
extent of the blood-filled region (Fig 5D, left image), 
and two adjacent sections were cut.  One section was 
imaged to show the distribution of DiI in the tumor 
(middle image), and the second section was stained 
with Masson’s trichrome to show the morphology of 
the section (right image).  The average distribution of 
nanoparticles in all imaged sections (Fig 5E, n = 4) 
showed that there was slightly more DiI signal per 
area in bloody regions, but in a paired t-test 
comparing DiI distribution in each tumor, this 
difference was not significant (p = 0.19).  This means 
that the additional 177Lu-LCP that accumulated after 
CA4P treatment distributed relatively evenly 
throughout the tumor and not only in the regions 
where the vasculature became permeable to blood 
cells.  In those regions where blood vessels were not 
permanently compromised, a temporary loss of the 
vessel endothelial cells’ flat structure—induced by 
CA4P’s inhibition of microtubule 
polymerization—may have created gaps between the 
cells and allowed the vessels to become more 
permeable to nanoparticles, leading to higher 
nanoparticle accumulation in non-bloody regions as 
well.   
 
Figure 5: Tumor Accumulation of 177Lu.  A) Subcutaneous tumor accumulation of 177Lu 24 h after i.v. administration of 177Lu-LCP with or without 100 mg/kg CA4P given i.p. 3 
h earlier.  UMUC3/3T3 tumors inoculated in nude mice; n = 8.  4T1 tumors inoculated in Balb/c mice; n = 4.  B16F10 tumors inoculated in C57BL/6 mice; n = 4-5.  B) Image of 
UMUC3/3T3 tumors untreated (left) or 24 h after treatment with 100mg/kg CA4P i.p. (right); Scale bars ~ 5mm.  C) Three tumor types incubated in formamide for 48 h at 60 
oC show blood in their centers when treated with CA4P; scale bar ~5mm.  D) UMUC3/3T3 tumor 24 h after treatment with 100 mg/kg CA4P; left panel: photograph of tumor 
tissue frozen in OCT during sectioning, bloody area outlined in black; middle panel: distribution of DiI-177Lu-LCP in tumor; right panel: H&E stained section adjacent to section 
taken for middle panel.  Scale bar = 1 mm.  E) Quantification of DiI-177Lu-LCP in bloody and non-bloody regions of tumor sections; n = 4. 
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Figure 6: Tumor Growth to 1,000 mm3.  A) Kaplan-Meier plot of mouse tumor growth to 1,000 mm3, n = 6-7.  B) Median time to reach 1,000 mm3 in mice receiving 250 μCi 
177Lu-LCP with or without 100 mg/kg CA4P i.p.  C) Tumor accumulation of 177Lu when tumors reach 1,000 mm3.   
 
Even though some nanoparticles are delivered to 
the apoptotic center of the tumor, internal radiation 
therapy is able to deliver treatment to faraway cells, 
increasing the utility of those particles delivered to the 
middle of the tumor.  Additionally, because 177Lu 
slowly decays independent of its environment (t1/2 = 
6.6 days), if the radiation remains in the tumor, it may 
prevent regrowth of tumor tissue. 
At this point, we had determined that CA4P 
induces enhanced accumulation of 177Lu-LCP, but had 
not determined whether this additional accumulation 
could be retained over a significant length of time.  It 
could be that as the pooled blood is filtered out of the 
tumor over time, it would take many of the particles 
and radioactive cargo with it; however, because 177Lu 
decays slowly over time, to be most effective, it 
should remain in the tumor as long as possible, 
continuously giving a low dose of radiation to the 
tumor.  To test this, mice bearing UMUC3/3T3 
tumors ~300-400 mm3 were treated with 100 mg/kg 
CA4P + 250 μCi 177Lu-LCP or controls.  Tumor 
volumes were measured daily, and the number of 
days it took for each tumor to reach 1,000 mm3 was 
determined.  When a tumor reached 1,000 mm3, the 
mouse was sacrificed and its tumor was dissected, 
weighed, and assessed for radioactivity.  We again 
found that CA4P + 177Lu-LCP significantly increased 
time to reach 1,000 mm3 compared to controls (Fig 6A 
and B), but more importantly, at the time each tumor 
reached 1,000 mm3, those tumors that had received 
CA4P + 177Lu-LCP still contained significantly more 
177Lu per gram of tumor than those that had received 
177Lu-LCP alone, even though it took on average ~30% 
longer for those tumors receiving CA4P + 177Lu-LCP 
to reach 1,000 mm3.  This means that those tumors 
were in fact able to retain the increased accumulation 
of 177Lu over an extended period of time.  The 
increased vessel permeability leading to the increased 
accumulation of 177Lu-LCP combined with the 
sustained retention of 177Lu in tumors means that 
CA4P does indeed increase the EPR of 177Lu-LCP. 
Choosing the most effective radionuclide 
177Lu is a relatively new radioisotope that is 
advancing toward the clinic in a variety of 
applications.  177Lu is a good model isotope because its 
6.6 day half-life provides the researcher a relatively 
long time to perform experiments before it decays, 
and the gamma component of its decay allows simple 
quantification of signal as well as live animal imaging 
using SPECT [1].  Despite these advantages, 177Lu has 
a fairly low beta energy (max = 0.5 Megaelectron-volts 
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(MeV)) with an average path length in tissue of only 
200-300 μm [21].  In a large, stroma-rich tumor model, 
it may be better to use an isotope with a more 
cytotoxic, higher energy beta emission that can reach 
farther away from the source, especially considering 
the heterogeneous and high stromal delivery of 
nanoparticles and the fact that treatment with CA4P 
may further induce regions of higher and lower 
nanoparticle density.  177Lu was therefore compared 
to 90Yttrium (90Y), a clinically used radioisotope [22, 
23] which has a max beta energy of 2.28 MeV and a 
half-life of 2.67 days.  Figure 7A compares the relative 
decay of 177Lu and 90Y over a period of seven days, 
while Figure 7B compares the previously calculated 
dose kernels for point sources of the two isotopes in 
units of absorbed dose (nanogray per decay per h 
over a given surface area) [24, 25].  While 90Y decays 
more quickly than 177Lu, its higher beta energy allows 
more energy to reach farther away from the source 
and impart more energy per interaction. 
Y is a trivalent transition metal that sits just 
above Lu in group 3 of the periodic table, and is 
therefore very chemically similar to Lu.  Not 
surprisingly, 90Y can also be easily encapsulated into 
LCP at the same high encapsulation efficiency as 177Lu 
(80-85%), and changing the LCP cargo from 177Lu to 
90Y does not change the morphology of the 
nanoparticles (Supplementary Fig S2A and S2B).  The 
injected activity per mouse of 90Y-LCP was set at 125 
μCi, half the dose of 177Lu-LCP.  This is common in 
publications comparing 90Y and 177Lu, often because 
the maximal tolerable dose for the delivered 177Lu is 
approximately twice as high as that of 90Y [26, 27].  In 
addition to displaying TEM images for LCP, Figure S2 
also reports the size, polydispersity index, zeta 
potential, and stability of LCP nanoparticles. 
 
 
Figure 7: Comparison of 177Lu and 90Y.  A) Different half-lives result in quicker drop-off of activity over time for 90Y.  B) Graphical display of dose kernels representing absorbed 
dose at increasing distances from a point source in an infinite water medium; decay products from 90Y are better able to impart energy to targets at longer distances from the 
source. 
 
Figure 8: Combination treatment prolongs tumor necrosis.  (A), top row: four days after CA4P monotherapy or combination treatment with 250 μCi 177Lu-LCP or 125 μCi 
90Y-LCP, tumors from several mice were dissected, sectioned, and stained for apoptotic cells (TUNEL, green).  Middle row: sections 8 μm away from TUNEL sections were 
stained with proliferation marker Ki-67 using IHC (brown).  Bottom Row: Ki-67 (yellow) overlaid with TUNEL (green).   Scale bar = 2 mm.  B) Quantification of TUNEL-positive 
area, n = 8 (CA4P), 30 (CA4P + 177Lu-LCP), 15 (CA4P + 90Y-LCP). 
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Figure 9: Mice bearing UMUC3-GFP/3T3-RFP tumors of volume 300 – 400 mm3 were treated as shown in A), n = 5-6 mice.  On Day 7, tumors were harvested, processed, 
sectioned in OCT, and stained.  B) Representative tumors shown from each group; green = UMUC3-GFP, orange = 3T3-RFP.  Scale bar = 2 mm.  C) 3T3-RFP signal isolated to 
show distribution. D) Caspase 3 distribution in adjacent section to (B).  E) Quantification of fibroblast density, total cell density, and apoptosis from each group.  Image resolution 
for quantification was enhanced by quantifying several random areas at higher magnification, ~4 mm2/section.  n = 9-13.  ***p < 0.001; *p < 0.05. 
 
In order to compare the efficacy of 177Lu and 90Y 
while also determining how their delivery 3 h after 
CA4P might affect the regrowth of apoptotic areas 
initially generated by CA4P, we measured the amount 
of apoptosis in large tumors four days after treatment 
with CA4P alone, or after combination therapy with 
CA4P + 177Lu-LCP or CA4P + 90Y-LCP.  After four 
days, the apoptosis caused by CA4P alone had been 
nearly completely healed and replaced with a high 
concentration of cells staining positively for the 
proliferation marker Ki-67, while significant apoptosis 
in the tumor centers still remained after combination 
treatment with CA4P + 90Y-LCP.  After treatment with 
CA4P + 177Lu-LCP, there was a large variation in the 
apoptotic and proliferative areas of various tumors.  
There was an increase in apoptotic area when 
compared to CA4P treatment alone, but this increase 
was not statistically significant.  These results 
suggested that 90Y-LCP would be more effective at 
inhibiting tumor growth than 177Lu-LCP, and may do 
so at least in part by maintaining the apoptotic region 
generated by CA4P.   
Tumor Growth Inhibition with 90Y-LCP and 
LPC 
In the following tumor growth inhibition study, 
UMUC3 cells stably expressing green fluorescence 
protein and 3T3 cells stably expressing red 
fluorescence protein (UMUC3-GFP/3T3-RFP) were 
inoculated into mice.  Treatment with CA4P + 
90Y-LCP was compared against CA4P + 177Lu-LCP, 
using 90Y-LCP monotherapy as a control alongside the 
untreated group.  CA4P + 90Y-LCP tumors grew 
significantly more slowly than any other group, 
including CA4P + 177Lu-LCP (Fig 9A).  At the study 
endpoint, the tumors were dissected and processed 
for frozen sectioning.  Two adjacent sections were 
stained: the first section was stained with DAPI, and 
fluorescence imaging was used to determine the 
distribution of UMUC3-GFP and 3T3-RFP cells in the 
tumor (Fig 9B and 9C); the second section was stained 
using IHC against cleaved Caspase 3 to quantify 
apoptosis (Fig 9D).  The average relative fibroblast 
density, total cell density, and apoptotic cell density 
across groups was calculated and showed that even 
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seven days after treatment with 90Y-LCP + CA4P, the 
tumors still contained significant amounts of 
apoptosis and the total cell density in the tumor had 
been decreased by 25%.  In addition, the fibroblast 
density had been greatly reduced, eliminating the 
aggressive and resistant “tumor nest” structure 
observed in many desmoplastic tumors (Fig 9E).   
Despite these changes to the tumor 
microenvironment, the tumors continued to slowly 
grow, although it is clear that their microenvironment 
had become much more susceptible to additional 
treatment.  The lower cell density had undoubtedly 
decreased the tumor’s interstitial pressure, and the 
loss of fibroblast structure had removed the physical 
barrier to the remaining tumor cells.  With the tumors 
in this weakened state, it was hypothesized that 
treatment using a potent nanoformulated drug may 
further decrease the growth rate of these now very 
large tumors.  Nanoparticles composed nearly 
entirely of cisplatin (termed Lipid-Platinum-Chloride 
particles, or LPC [13, 20]; characterized in 
supplementary Fig S2 and in much greater detail in 
the referenced publications) have been shown to be 
highly effective against a variety of tumors, but have 
been ineffective in treating large, desmoplastic tumors 
such as this stroma-rich bladder cancer model.  
Although cisplatin is generally a potent and effective 
drug, the fibroblasts in large UMUC3/3T3 tumors 
physically prevent the nanoparticles from reaching 
the tumor nest in addition to secreting the 
resistance-forming chemokine Wnt16b in response to 
treatment [2].   In our final tumor inhibition 
experiment, we examined whether two low doses of 
LPC given once tumors had grown very large (~800 
mm3) could significantly slow the growth of untreated 
tumors or tumors that had previously been given 100 
mg/kg CA4P + 125 μCi 90Y-LCP (Fig 10). 
To fairly compare the efficacy of LPC on 
previously treated and untreated tumors, LPC was 
initially given when the average volume of tumors 
within each group reached ~800 mm3.  At those 
points, half of the untreated tumors and half of the 
previously treated tumors received a total of two 
doses of 1.5 mg/kg LPC, administered i.v. through 
tail vein injection on two consecutive days (Fig 10A).  
Groups were divided evenly to maintain the average 
tumor volume of each group.   
 
Fig 10: Mice bearing UMUC3/3T3 tumors of volume 300 – 400 mm3 were either treated with 100 mg/kg CA4P + 125 μCi 90Y-LCP or left untreated (n = 10).  When tumors 
reached ~800 mm3, half of the mice from each group (n = 5) were treated with 1.5 mg/kg CDDP formulated in LPC nanoparticles on two consecutive days.  A) Tumor volumes 
recorded daily.  B)  All four groups normalized to the volume of each individual tumor at the time of initial CDDP dose.  *p < 0.05; ***p < 0.001. 
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All tumors were then normalized to the date at 
which they received LPC and their volume on that 
date (Fig 10B).   The rate of tumor growth from the 
date of initial LPC treatment (or paired untreated 
controls) was then quantified.  In tumors that initially 
received CA4P + 90Y-LCP, a significant difference in 
growth rate was observed between those tumors that 
received additional LPC treatment and tumors that 
received no additional treatment.  In contrast, in 
tumors that initially received no treatment, additional 
treatment with LPC induced no distinguishable 
change in growth rate compared to completely 
untreated tumors.  This suggests that the 
treatment-induced changes in the tumor 
microenvironment shown in Fig 9 allowed LPC to 
provide further tumor growth inhibition even in very 
large tumors.  By increasing the dose of LPC or the 
duration of treatment, further tumor growth 
inhibition can be expected. 
To test our hypothesis that these weakened 
tumors were still more susceptible to increased 
nanoparticle accumulation—whether because of 
lower total cell density or otherwise—we treated 
300-400 mm3 tumors with CA4P + 90Y-LCP, six days 
later injected 177Lu-LCP, and 24 h after that, sacrificed 
the mice and measured the tumor accumulation of 
177Lu via gamma scintillation counting.  We compared 
the accumulation of 177Lu in these tumors to the 
accumulation of 177Lu in previously untreated very 
large (~800 mm3) tumors that had been dissected 24 h 
after the mice received 177Lu-LCP.  After normalizing 
for tumor mass, we found that those tumors that had 
been previously treated with CA4P + 90Y-LCP had 
accumulated, on average, 40% more 177Lu than those 
tumors with no prior treatment, although this 
difference was not statistically significant (p ~ 0.1). 
Toxicity Considerations 
Lastly, we determined if there was any toxicity 
induced by these radiation and combination 
treatments.  Because internal radiotherapy imparts a 
slow, continuous dose to tissues, the cumulative 
toxicity generated ten days after treatment was 
measured.  There was no observed renal or hepatic 
toxicity observed (Table 1A), but as expected, the 
radiation treatments induced a tolerable decrease in 
white blood cell count and platelet count.  
Interestingly, the treatments incorporating 90Y 
induced less toxicity than the treatments using 177Lu, 
even though the 90Y was more effective at inhibiting 
tumor growth.  No toxicity was observed in 
H&E-stained organ sections (Supplementary Fig S3). 
 
Table 1: Toxicity studies, measured 10 days after treatment in immunocompetent CD-1 mice to test cumulative radiation toxicity: A) 
Serum protein values for all treatment groups, measuring blood urea nitrogen (BUN), creatinine, alanine aminotransferase (ALT), and 
aspartate aminotransferase (AST). B) Whole blood analysis for all treatment groups, measuring white blood cell count (WBC), hematocrit 
(HCT), mean cell volume (MCV), red blood cell count (RBC), hemoglobin count (HGB), and platelet count (PLT). 
 
 
 
WBC 
(103/μl)
HCT          
(%)
MCV          
(fl)
RBC 
(106/μl)
HGB      
(g/dl)
PLT 
(103/μl)
Untreated 3.8 ± 0.4 57.5 ± 0.9 60.6 ± 1.1  9.5 ± 0.3 15.6 ± 0.3 936 ± 30
CA4P 3.4 ± 0.4 50.3 ± 3.6 52.8 ± 3.6 9.3 ± 0.3 15.5 ± 0.4 980 ± 39
250 uCi 177Lu-LCP 0.4 ± 0.1 42.9 ± 1.8 53.4 ± 1.8 8.0 ± 0.1 12.7 ± 0.2 221 ± 35
125 uCi 90Y-LCP 0.8 ± 0.1 36.8 ± 1.1 49.7 ± 0.7 7.4 ± 0.3 11.9 ± 0.5 556 ± 131
CA4P + 250 uCi 177Lu-LCP 0.4 ± 0.1 43.5 ± 4.5 56.3 ± 1.7 7.7 ± 0.6 12.4 ± 0.9 150 ± 25
CA4P + 125 uCi 90Y-LCP 0.8 ± 0.1 38.6 ± 3.1 53.7 ± 2.9 7.2 ± 0.2 11.8 ± 0.5 463 ± 45
CA4P + 125 uCi 90Y-LCP + LPC 1.1 ± 0.1 41.0 ± 3.5 53.2 ± 2.7 7.7 ± 0.4 13.1 ± 0.7 384 ± 38
Normal Range 2.6 - 10.1 32.8 - 48.0 42.3 - 55.9 6.5 - 10.1 10.1 - 16.1 780 - 1540
BUN mg/dL Creatinine mg/dL AST U/L ALT U/L
Untreated 19.0 ± 1.4 0.18 ± 0.03 34.25 ± 1.7  39.0 ± 1.7
CA4P 17.5 ± 0.6 0.2 37.0 ± 3.2 44.3 ± 4.6
250 uCi 177Lu-LCP 18.5 ± 1.3 0.2 29.3 ± 2.2 45.5 ± 2.3
125 uCi 90Y-LCP 22.0 ± 1.7 0.2 29.5 ± 2.2 44.3 ± 3.3
CA4P + 250 uCi 177Lu-LCP 23.5 ± 1.9 0.2 34.3 ± 2.5 40.3 ± 2.4
CA4P + 125 uCi 90Y-LCP 21.8 ± 1.3 0.2 33.5 ± 1.8 44.3 ± 2.2
CA4P + 125 uCi 90Y-LCP + LPC 19.6 ± 0.9 0.2 ± 0.02 60.2 ± 23.7 37.2 ± 6.6
Normal Range 8-33 0.2-0.9 54-298 17-77
A
B
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Discussion 
While a recent study has shown that vessel 
occlusion caused by CA4P prevents nanoparticles 
from entering the tumor center [11], we have shown 
that CA4P induces an increased EPR effect, allowing a 
greater accumulation and retention of nanoparticles 
throughout the tumor.  We have observed that the 
increase in nanoparticle accumulation comes 
alongside vascular hemorrhage in the tumor, and it 
makes sense that if blood cells can enter the tumor 
center, the much smaller nanoparticles also slowly 
flowing through the broken vasculature would not be 
kept at the tumor periphery.  We have also observed 
that the pooled blood in tumors dissected 24 h after 
CA4P treatment had not yet coagulated, suggesting 
the presence of at least a slow flow of blood capable of 
bringing nanoparticles into the tumor.  What, then, 
could cause the discrepancy in the data?  The 
seemingly contradictory study also reports vascular 
hemorrhage, but they administer their nanoparticles 
at the same time that they administer the CA4P.  It 
could be that the immediate vascular occlusion effect 
of CA4P, which occurs before any hemorrhage begins, 
stops all flow into the center of the tumor, trapping 
the nanoparticles on the outer rim.  If their particles 
quickly clear from circulation, by the time vascular 
hemorrhage begins, there are no particles left to enter 
the inner regions of the tumor.  In contrast, our 
nanoparticles are given 3 h after CA4P treatment, at 
which point vascular hemorrhage may have already 
begun, allowing an increased amount of particles into 
the tumor. 
If this is the case, it is worth discussing whether 
one approach is more effective than another.  This 
answer must be given in light of the tumor model 
being studied.  In the recent article, CA4P alone is able 
to cause vascular hemorrhage across nearly the entire 
tumor in just four hours, and only a small portion of 
the tumor requires nanoparticle treatment.  Only 
having a small portion of the tumor available for 
nanoparticle deposition may greatly reduce the 
overall tumor accumulation of the particle, but in this 
case, the authors show that this is all that is needed.  
In our case, although ultrasound images suggest that 
a large percentage of the tumor is not well perfused 3 
h after CA4P treatment, some of this vessel occlusion 
is transient.  The ability of vasculature in 
UMUC3/3T3 tumors to partially repair after 
treatment with CA4P may be due in part to their 
stroma-vessel structure, as the organized fibroblasts 
which line the vessel endothelium may provide 
enough structural support to allow vessel repair.  In 
addition, the TUNEL-positive area 24 h after 
treatment is variable in size, and is also able to be 
replaced with proliferating cells over time.  In this 
case, we have shown that the heightened nanoparticle 
accumulation and retention in the tumor is vital for 
effective tumor inhibition.    Strategies to deal with 
these resistant and aggressive tumors may be 
different from those aiming to treat tumors with less 
stroma.   
It is important to note that the large tumor model 
used in this study was chosen not only because of its 
size, but because its size provided it with 
characteristics that are difficult to treat.  The difficulty 
of slowing down the growth of an aggressive, 
desmoplastic tumor with a mature microenvironment 
requires a synergistic approach that provides the right 
treatments at the right times.  CA4P simultaneously 
causes cell death in a significant portion of the tumor 
and induces an increased EPR in the tumor.  The cell 
death in the middle of the tumor is maintained by 
90Y-LCP, which also presents cytotoxicity to the 
surviving cells in the tumor.  Changes in the tumor 
microenvironment in response to this combination 
therapy then allow treatment with LPC nanoparticles, 
which are completely ineffective in tumors that have 
not been previously treated.  Although these 
treatments do not cause tumor remission, they 
generate significant tumor growth inhibition in this 
tumor model that will grow tenfold in ten days if left 
untreated. 
Of course, clinical implementation of this 
combination therapy must be modified to minimize 
systemic toxicity.  While intravenous administration 
of 90Y-LCP presents a good model of internal radiation 
therapy’s effectiveness in combination with CA4P, the 
well-known uptake of nanoparticles into clearing 
organs presents a compelling argument against this 
injection route.  This subject has been recently 
reviewed [28], and perhaps the best future use for 
177Lu/90Y-LCP is in selective internal radiation 
therapy (SIRT) [29, 30].  SIRT locally delivers 
90Y-microspheres around primary or metastatic 
tumors in the liver via a catheter placed into the 
hepatic artery.  The large size of the microspheres 
prevents them from entering the tumor capillaries, so 
a larger dose must be given in order to provide 
treatment to all tumor cells, resulting in off-target 
toxicity to the liver and lung.  Local delivery of 
177Lu/90Y-LCP via hepatic catheter may result in 
better tumor penetration than 90Y-microspheres and 
less off-target dose than systemic administration of 
LCP, increasing the dose to the tumor while 
decreasing off-target effects.  Combination therapy 
with CA4P against desmoplastic tumors in the liver 
would not only cause massive apoptosis in the tumor 
centers, but also induce an increased accumulation of 
nanoparticles in the tumor and prime the 
microenvironment for further treatment. 
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Conclusion 
In conclusion, we have generated significant 
tumor growth inhibition in a large, desmoplastic 
tumor model by using CA4P to increase the tumor 
EPR and allow increased accumulation and retention 
of radioactive nanoparticles for internal radiation 
therapy.  This combination therapy decreases the 
fibroblast and overall cellular density in the tumor, 
allowing effective treatment with a second 
nanoparticle system containing cisplatin—an 
approach which may also be effective as a local 
combination therapy against desmoplastic cancers in 
the liver. 
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